Hodgkin lymphoma: hypodense lesions in mediastinal masses.
Adrian DamekLars KurchFriedrich Christian FrankeAndishe AttarbaschiAuke BeishuizenMichaela CepelovaFrancesco CeppiStephen DawKarin DieckmannAna Fernández-TeijeiroTobias FeuchtingerJamie E FlerlageAlexander FossåThomas W GeorgiDirk HasencleverAndrea HraskovaJonas KarlenTomasz KlekawkaRegine KlugeDieter KörholzJudith Landman-ParkerThierry LeblancChristine Mauz-KörholzMarkus MetzlerJane PearsJonas SteglichAnne UyttebroeckDirk VordermarkWilliam Hamish WallaceWalter Alexander WohlgemuthDietrich StoevesandtPublished in: Scientific reports (2024)
Hypodense volumes (HDV) in mediastinal masses can be visualized in a computed tomography scan in Hodgkin lymphoma. We analyzed staging CT scans of 1178 patients with mediastinal involvement from the EuroNet-PHL-C1 trial and explored correlations of HDV with patient characteristics, mediastinal tumor volume and progression-free survival. HDV occurred in 350 of 1178 patients (29.7%), typically in larger mediastinal volumes. There were different patterns in appearance with single lesions found in 243 patients (69.4%), multiple lesions in 107 patients (30.6%). Well delineated lesions were found in 248 cases (70.1%), diffuse lesions were seen in 102 cases (29.1%). Clinically, B symptoms occurred more often in patients with HDV (47.7% compared to 35.0% without HDV (p = 0.039)) and patients with HDV tended to be in higher risk groups. Inadequate overall early- 18 F-FDG-PET-response was strongly correlated with the occurrence of hypodense lesions (p < 0.001). Patients with total HDV > 40 ml (n = 80) had a 5 year PFS of 79.6% compared to 89.7% (p = 0.01) in patients with HDV < 40 ml or no HDV. This difference in PFS is not caused by treatment group alone. HDV is a common phenomenon in HL with mediastinal involvement.
Keyphrases
- computed tomography
- lymph node
- end stage renal disease
- hodgkin lymphoma
- ejection fraction
- ultrasound guided
- chronic kidney disease
- newly diagnosed
- positron emission tomography
- randomized controlled trial
- pet ct
- magnetic resonance imaging
- depressive symptoms
- patient reported outcomes
- risk assessment
- study protocol
- low grade
- open label
- replacement therapy